| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* First Department of Internal Medicine and
Department of Pathology, Ehime University School of Medicine, Ehime, Japan
The use of receptor antagonists for chemokines is an alternative approach to blocking chemokine actions and has the potential to provide novel therapeutics. We determined the receptor antagonist properties of murine N-terminally truncated secondary lymphoid tissue chemokine (SLC)/6Ckine/CCR ligand 21 analogs and evaluated the preventive effects of SLC antagonists on chronic graft-vs-host disease (GVHD) in a murine model by blocking the homing of donor CCR7-expressing T cells into the recipient’s lymphoid organs. SLC analogs truncated >4 aa residues from the N terminus showed a loss of chemotaxis and Ca2+ influx of CCR7-expressing cells and also inhibited SLC-stimulated chemotaxis and SLC-induced Ca2+ influx completely. To determine whether SLC antagonist inhibits the development of chronic GVHD, chronic GVHD was induced by injecting DBA/2 spleen cells into (C57BL/6 x DBA/2) F1 mice. Total numbers of spleen cells and host B cells, serum levels of IgE, and of total IgG and IgG1 of anti-DNA Abs in SLC antagonist-treated GVHD mice were significantly lower than those in control PBS-treated GVHD mice. This was due to a reduction in the levels of activated donor CD4+ T cells and a decrease in IL-4 production, resulting in a reduction in the numbers of activated host B cells. Therefore, our results suggest that SLC antagonist has beneficial effects for the prevention of chronic GVHD.
This article has been cited by other articles:
|
|
 |
|
  S. El-Chemaly, D. Malide, E. Zudaire, Y. Ikeda, B. A. Weinberg, G. Pacheco-Rodriguez, I. O. Rosas, M. Aparicio, P. Ren, S. D. MacDonald, et al. Abnormal lymphangiogenesis in idiopathic pulmonary fibrosis with insights into cellular and molecular mechanisms PNAS, March 10, 2009; 106(10): 3958 - 3963. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, R. R. Seethala, Q. Zhang, W. Gooding, C. van Waes, H. Hasegawa, and R. L. Ferris Autocrine and Paracrine Chemokine Receptor 7 Activation in Head and Neck Cancer: Implications for Therapy J Natl Cancer Inst, April 2, 2008; 100(7): 502 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Xu, K. Aoyama, M. Kusumoto, A. Matsuzawa, E. C. Butcher, S. A. Michie, T. Matsuyama, and T. Takeuchi Lack of lymphoid chemokines CCL19 and CCL21 enhances allergic airway inflammation in mice Int. Immunol., June 1, 2007; 19(6): 775 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Damas, C. Smith, E. Oie, B. Fevang, B. Halvorsen, T. Waehre, A. Boullier, U. Breland, A. Yndestad, O. Ovchinnikova, et al. Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental Atherosclerosis: Possible Pathogenic Role in Plaque Destabilization Arterioscler Thromb Vasc Biol, March 1, 2007; 27(3): 614 - 620. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Varona, V. Cadenas, L. Gomez, C. Martinez-A, and G. Marquez CCR6 regulates CD4+ T-cell-mediated acute graft-versus-host disease responses Blood, July 1, 2005; 106(1): 18 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Lee New approaches for preventing and treating chronic graft-versus-host disease Blood, June 1, 2005; 105(11): 4200 - 4206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Chun, C.-C. Yin, J.-Z. Song, M.-X. Liu, J.-H. Piao, Q. Lin, X.-B. Wang, and H.-L. Huang Soluble Expression of Recombinant Human Secondary Lymphoid Chemokine (SLC) in E. coli and Research on Its In Vitro and In Vivo Bioactivity J. Biochem., December 1, 2004; 136(6): 769 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Pilkington, I. Clark-Lewis, and S. R. McColl Inhibition of Generation of Cytotoxic T Lymphocyte Activity by a CCL19/Macrophage Inflammatory Protein (MIP)-3{beta} Antagonist J. Biol. Chem., September 24, 2004; 279(39): 40276 - 40282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Petkovic, C. Moghini, S. Paoletti, M. Uguccioni, and B. Gerber I-TAC/CXCL11 is a natural antagonist for CCR5 J. Leukoc. Biol., September 1, 2004; 76(3): 701 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Anderson, J. M. McNiff, C. Matte, I. Athanasiadis, W. D. Shlomchik, and M. J. Shlomchik Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease Blood, September 1, 2004; 104(5): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Petkovic, C. Moghini, S. Paoletti, M. Uguccioni, and B. Gerber Eotaxin-3/CCL26 Is a Natural Antagonist for CC Chemokine Receptors 1 and 5: A HUMAN CHEMOKINE WITH A REGULATORY ROLE J. Biol. Chem., May 28, 2004; 279(22): 23357 - 23363. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
